Neoplasia — MCQs

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 311: Which structure is NOT typically found in the anterior mediastinum?

A. Teratoma
B. Thymic tumors
C. Thyroid tumors
D. Neurofibroma (Correct Answer)

Explanation: To master mediastinal masses for NEET-PG, it is essential to divide the mediastinum into compartments. The **Anterior Mediastinum** is the space between the sternum and the pericardium, while the **Posterior Mediastinum** is the space between the pericardium and the spine. ### Why Neurofibroma is the Correct Answer **Neurofibroma** is a nerve sheath tumor [2]. In the mediastinum, neurogenic tumors (including neurofibromas, schwannomas, and ganglioneuromas) are the most common primary tumors of the **Posterior Mediastinum**. They arise from the spinal nerve roots or the sympathetic chain. Therefore, finding a neurofibroma in the anterior compartment is highly atypical. ### Why the Other Options are Incorrect The anterior mediastinum is characterized by the **"4 Ts"** mnemonic: * **Thymic tumors (Option B):** The thymus is the primary organ of the anterior compartment; thymomas are the most common anterior mediastinal mass in adults [1]. * **Teratoma (Option A):** Germ cell tumors (GCTs), specifically mature teratomas, are frequently located here [1]. * **Thyroid tumors (Option C):** Ectopic thyroid tissue or substernal extensions of a goiter (retrosternal goiter) commonly present as anterior masses. * **"Terrible" Lymphoma:** (Though not listed, it completes the 4 Ts) [1]. ### High-Yield Clinical Pearls for NEET-PG * **Most common mediastinal mass overall:** Neurogenic tumors (located in the posterior mediastinum). * **Thymoma association:** Frequently associated with **Myasthenia Gravis** (30-50% of thymoma patients have MG) [3]. * **Imaging Gold Standard:** Contrast-Enhanced CT (CECT) is the investigation of choice for localizing and characterizing mediastinal masses. * **Age Factor:** In children, neurogenic tumors are the most common; in adults, thymomas are more prevalent. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 571-574. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Peripheral Nerves and Skeletal Muscles, p. 1250. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, p. 634.

Question 312: Which of the following genes promote epithelial-mesenchymal transition and are important metastatic genes in epithelial tumors?

A. MYC
B. SNAIL
C. TWIST
D. Both SNAIL and TWIST (Correct Answer)

Explanation: **Explanation:** The correct answer is **Both SNAIL and TWIST**. **1. Understanding Epithelial-Mesenchymal Transition (EMT):** EMT is a biological process where polarized epithelial cells lose their adhesion and apical-basal polarity, gaining a migratory mesenchymal phenotype. This is a critical step in the **invasion-metastasis cascade**. * **Mechanism:** The hallmark of EMT is the **downregulation of E-cadherin** (the "glue" that holds epithelial cells together) [1]. * **Role of SNAIL and TWIST:** These are specific transcription factors that act as master regulators of EMT [1]. They directly bind to the promoter of the E-cadherin gene (*CDH1*) and **repress its transcription** [1]. By suppressing E-cadherin and upregulating mesenchymal markers like Vimentin and Smooth Muscle Actin, they enable tumor cells to detach from the primary mass, breach the basement membrane, and enter the circulation. **2. Why other options are incorrect:** * **MYC (Option A):** While *MYC* is a potent proto-oncogene involved in cell cycle progression, metabolism, and transformation, it is not a primary driver of EMT. It typically promotes proliferation rather than the specific phenotypic switch to a mesenchymal state. **3. High-Yield Clinical Pearls for NEET-PG:** * **E-cadherin:** Loss of E-cadherin is the "molecular signature" of EMT and is characteristically seen in **Lobular Carcinoma of the Breast** and **Diffuse Gastric Cancer** (Signet ring cell type). * **TGF-β:** This cytokine is a major inducer of EMT in the tumor microenvironment [1]. * **Metastasis:** EMT is reversible. Once the tumor cell reaches a distant site, it undergoes **MET (Mesenchymal-Epithelial Transition)** to form a secondary colony. * **Transcription Factors:** Remember the triad of EMT regulators: **SNAIL, SLUG, and TWIST.** **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 317-318.

Question 313: Defects in DNA repair are associated with an increased risk of malignancy in which of the following conditions?

A. Xeroderma pigmentosum (Correct Answer)
B. Ichthyosis
C. Mosaicism
D. None of the above

Explanation: **Explanation:** **1. Why Xeroderma Pigmentosum (XP) is correct:** Xeroderma pigmentosum is a classic example of an autosomal recessive disorder characterized by a defect in **Nucleotide Excision Repair (NER)** [1]. Under normal conditions, NER enzymes repair DNA damage (specifically pyrimidine dimers) caused by Ultraviolet (UV) radiation. In XP patients, this repair mechanism is non-functional, leading to the accumulation of mutations in keratinocytes. This results in a 2,000-fold increased risk of skin cancers, including Basal Cell Carcinoma, Squamous Cell Carcinoma, and Malignant Melanoma, often occurring in early childhood [1]. **2. Why the other options are incorrect:** * **Ichthyosis:** This refers to a group of genetic skin disorders characterized by dry, thickened, and scaly skin (e.g., Ichthyosis vulgaris). It is primarily a disorder of **keratinization** or filaggrin synthesis, not a defect in DNA repair. * **Mosaicism:** This describes a condition where an individual has two or more genetically different cell lines derived from a single zygote (due to post-zygotic mutation). While mosaicism can be seen in some genetic syndromes, it is a pattern of genetic inheritance/expression rather than a specific mechanism of DNA repair failure. **3. NEET-PG High-Yield Clinical Pearls:** * **Other DNA Repair Defect Syndromes:** * **Mismatch Repair (MMR):** Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer). * **Homologous Recombination:** BRCA1/BRCA2 mutations (Breast/Ovarian cancer) and Bloom Syndrome [1]. * **DNA Cross-link Repair:** Fanconi Anemia (leads to bone marrow failure and AML) [1]. * **Ataxia-Telangiectasia:** Defect in the *ATM* gene, which senses DNA double-strand breaks [1]. * **Key Association:** XP patients must strictly avoid sunlight ("Children of the Night"). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 322-323, 332-333.

Question 314: Which of the following is NOT a criterion for staging of a disease?

A. Size of primary tumor
B. Degree of differentiation (Correct Answer)
C. Extension to lymph nodes
D. Metastases

Explanation: ### Explanation The fundamental concept tested here is the distinction between **Staging** and **Grading** of a neoplasm. **Why "Degree of differentiation" is the correct answer:** The degree of differentiation (how much the tumor cells resemble their normal counterparts) is the primary criterion for **Grading** [2]. Grading is a histological assessment performed by a pathologist under a microscope. It categorizes tumors (e.g., Grade I to IV) based on cellular pleomorphism, mitotic activity, and architectural features. While grading provides prognostic value, it is **not** a component of staging. **Why the other options are incorrect:** Options A, C, and D are the three pillars of the **TNM Staging System**, which is the most widely used clinical staging method [1]: * **Size of primary tumor (T):** Refers to the local extent and dimensions of the tumor [1]. * **Extension to lymph nodes (N):** Refers to the involvement of regional lymph nodes [1]. * **Metastases (M):** Refers to the presence of distant spread to other organs [3]. Staging is based on clinical, radiological, and surgical findings and is generally considered a **better predictor of prognosis** than grading. ### High-Yield Clinical Pearls for NEET-PG: * **Staging vs. Grading:** Staging (TNM) is clinical/anatomical; Grading is histological [2]. * **Prognostic Significance:** In most cancers, **Staging is more important** than Grading for determining prognosis and treatment protocols. * **Exceptions:** In certain cancers like Soft Tissue Sarcomas and Transitional Cell Carcinoma of the bladder, the **Grade** is a critical determinant of management. * **AJCC:** The American Joint Committee on Cancer (AJCC) is the body that standardizes TNM staging criteria. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 236-237. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 207-208. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 280.

Question 315: Which of the following is not a carcinogenic virus?

A. Hepatitis B
B. Hepatitis C
C. Molluscum contagiosum (Correct Answer)
D. HPV

Explanation: **Explanation:** The correct answer is **Molluscum contagiosum**. While many viruses are implicated in human oncogenesis, Molluscum contagiosum virus (MCV) is a member of the **Poxvirus** family that causes benign, self-limiting cutaneous infections characterized by umbilicated papules [1]. It does not possess transforming properties or oncogenes that lead to malignancy [3]. **Why the other options are incorrect (Carcinogenic Viruses):** * **Hepatitis B (HBV):** A DNA virus associated with **Hepatocellular Carcinoma (HCC)** [3]. It promotes carcinogenesis through chronic inflammation, hepatocyte regeneration, and the **HBx protein**, which disrupts cell cycle control and inhibits p53. * **Hepatitis C (HCV):** An RNA virus also strongly linked to **HCC** [3]. Unlike HBV, it does not integrate into the host genome; instead, it causes cancer via chronic immune-mediated liver injury and oxidative stress. * **HPV (Human Papillomavirus):** High-risk types (16, 18) are major causes of cervical, oropharyngeal, and anogenital cancers [3]. Its oncogenicity is driven by **E6** (inhibits p53) and **E7** (inhibits RB) proteins [4]. **High-Yield Clinical Pearls for NEET-PG:** * **DNA Oncogenic Viruses:** HPV, EBV (Burkitt lymphoma, Nasopharyngeal Ca), HBV, HHV-8 (Kaposi Sarcoma) [3]. * **RNA Oncogenic Viruses:** HTLV-1 (Adult T-cell Leukemia/Lymphoma) and HCV [3]. * **Molluscum Contagiosum Histology:** Look for **Henderson-Patterson bodies** (large, eosinophilic intracytoplasmic inclusion bodies) in the epidermis [2]. * **Direct vs. Indirect Carcinogens:** HBV/HCV are often considered "indirect" as they trigger cancer through chronic inflammation, whereas HPV is a "direct" carcinogen via viral oncogenes. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1177-1178. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, p. 1178. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 219-220. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 334-335.

Question 316: Which of the following statements regarding Kaposi's Sarcoma is true?

A. Does not occur in non-HIV positive persons.
B. Has increasing incidence among AIDS patients. (Correct Answer)
C. No gastrointestinal bleeding.
D. Uncommon among homosexual HIV positive individuals.

Explanation: **Explanation:** **Kaposi’s Sarcoma (KS)** is a vascular neoplasm caused by **Human Herpesvirus 8 (HHV-8)**. It is the most common neoplasm associated with AIDS, defining the progression from HIV to AIDS [1]. 1. **Why Option B is Correct:** In the context of the HIV pandemic, KS remains the most frequent tumor in AIDS patients. While the widespread use of Highly Active Antiretroviral Therapy (HAART) has reduced the overall mortality and severity [2], the **incidence remains significantly high** among untreated or late-diagnosed AIDS patients compared to the general population [1]. It is thousands of times more common in AIDS patients than in the general population. 2. **Why Other Options are Incorrect:** * **Option A:** KS occurs in four distinct clinical settings: **Classic** (older Mediterranean/Eastern European men), **Endemic** (African), **Iatrogenic** (organ transplant recipients), and **AIDS-associated**. Therefore, it *does* occur in non-HIV individuals. * **Option C:** KS is a systemic disease. While skin lesions are classic [3], **visceral involvement** is common in the AIDS-associated type. The **Gastrointestinal tract** is a frequent site of extracutaneous involvement, often leading to occult or overt GI bleeding. * **Option D:** In the early HIV epidemic, KS was approximately 20 times more common in **homosexual/bisexual men** than in other HIV risk groups (like IV drug users), likely due to the sexual transmission of HHV-8. **High-Yield Clinical Pearls for NEET-PG:** * **Pathogenesis:** HHV-8 (KSHV) encodes a viral G-protein coupled receptor that stimulates VEGF, leading to angiogenesis. * **Morphology:** Characterized by **slit-like vascular spaces** containing RBCs and spindle-shaped stromal cells [3]. * **Marker:** CD34 (vascular marker) and LANA-1 (HHV-8 marker) are positive on IHC. * **Treatment:** HAART is the primary treatment for AIDS-associated KS; local therapies or chemotherapy (Doxorubicin) are used for advanced cases [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 261-262. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 263-264. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 526-527.

Question 317: Which of the following are required for normal cell growth?

A. Protooncogenes
B. Tumor suppressor genes
C. DNA repair genes
D. All of the above (Correct Answer)

Explanation: Normal cell growth is a highly regulated process that relies on a delicate balance between "accelerators" and "brakes." [1] The correct answer is **All of the above** because these three classes of genes function as the regulatory framework of the cell cycle. ### **Explanation of Concepts** 1. **Proto-oncogenes (The Accelerators):** These are normal genes that code for proteins promoting cell proliferation (e.g., growth factors, receptors, and signal transducers). [1], [2] They are essential for physiological growth, tissue repair, and development. [3] 2. **Tumor Suppressor Genes (The Brakes):** These genes (e.g., *RB*, *TP53*) produce proteins that inhibit cell cycle progression in response to DNA damage or metabolic stress. [1] They prevent uncontrolled proliferation, ensuring cells only divide when conditions are optimal. 3. **DNA Repair Genes (The Mechanics):** These genes (e.g., *BRCA1/2*, Mismatch repair genes) monitor and fix errors in the genetic code. [4] Without them, mutations would accumulate during every cell division, leading to genomic instability and cell death or malignant transformation. [4] ### **Why "All of the Above" is Correct** Normal growth is not just about "speeding up" (Proto-oncogenes); it requires "stopping" at checkpoints (Tumor suppressors) and "maintaining" the blueprint (DNA repair). If any of these three systems fail, the result is either cell death or the development of **Neoplasia**. ### **High-Yield NEET-PG Pearls** * **Oncogenes:** When a proto-oncogene undergoes a **gain-of-function** mutation (only one allele needed), it becomes an oncogene. * **Knudson’s Two-Hit Hypothesis:** Most tumor suppressor genes require **loss-of-function** mutations in **both alleles** to promote cancer. * **The "Guardian of the Genome":** *TP53* is the most commonly mutated gene in human cancers; it acts by inducing cell cycle arrest (via p21) or apoptosis (via BAX). [4] * **Caretaker vs. Gatekeeper:** DNA repair genes are often called "Caretakers," while tumor suppressors are "Gatekeepers." **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 291-292. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 292-293. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 228-229. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 226-227.

Question 318: The Nottingham histologic score does not include which of the following?

A. Tubule formation
B. Nuclear pleomorphism
C. Mitotic rate
D. Presence or absence of metastases (Correct Answer)

Explanation: ### Explanation The **Nottingham Histologic Score** (also known as the Elston-Ellis modification of the Scarff-Bloom-Richardson grading system) is the standard method used to determine the **grade** of invasive breast carcinoma. **Why "Presence or absence of metastases" is correct:** In oncology, **Grading** and **Staging** are two distinct concepts. The Nottingham score is a **grading system**, which assesses the degree of differentiation and aggressiveness of the tumor cells under a microscope. The presence or absence of metastases is a component of **Staging** (specifically the 'M' in the TNM classification), which describes the anatomical extent of the disease [1], [2]. Therefore, it is not part of the histologic score. **Why the other options are incorrect:** The Nottingham score is calculated by assigning a score of 1 to 3 for three specific morphological features: * **Tubule formation:** Evaluates how much of the tumor forms recognizable duct-like structures (More tubules = Lower grade). * **Nuclear pleomorphism:** Evaluates the variation in size and shape of the tumor cell nuclei (Less variation = Lower grade). * **Mitotic rate:** Evaluates the number of cells undergoing division per 10 high-power fields (Lower mitosis = Lower grade). The sum of these three scores (ranging from 3 to 9) determines the final Grade (I, II, or III). ### High-Yield Clinical Pearls for NEET-PG: * **Grading vs. Staging:** Generally, **Staging** (TNM) is a better predictor of overall prognosis than Grading [1]. * **Score Ranges:** * 3–5: Grade I (Well-differentiated) * 6–7: Grade II (Moderately differentiated) * 8–9: Grade III (Poorly differentiated) * **Mitotic Count:** This is the most objective but also the most variable component of the score. * **Application:** This grading system is specifically used for **Invasive Breast Carcinoma**, not for *in situ* lesions. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1072. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 236-237.

Question 319: Which type of DCIS typically presents as a palpable abnormality?

A. Comedocarcinoma
B. Non-comedo DCIS
C. Paget's disease of the nipple (Correct Answer)
D. None of the above

Explanation: **Explanation:** The correct answer is **Paget’s disease of the nipple**. **1. Why Paget’s disease of the nipple is correct:** Paget’s disease of the nipple is a unique clinical manifestation of Ductul Carcinoma In Situ (DCIS) where malignant cells (Paget cells) migrate from the underlying ductal system into the epidermis of the nipple and areola [1]. Unlike most forms of DCIS, which are typically subclinical and detected only via microcalcifications on mammography, Paget’s disease presents as a **palpable abnormality** or a visible skin lesion (erythematous, eczematous, or crusting) [1]. Crucially, in about 50-60% of cases, an underlying palpable mass is present, which often signifies an associated invasive carcinoma [1]. **2. Why other options are incorrect:** * **Comedocarcinoma:** This is the most aggressive subtype of DCIS, characterized by high-grade nuclei and central "comedo-like" necrosis [2]. While it frequently shows extensive microcalcifications on mammography, it rarely presents as a palpable mass unless it has already progressed to invasive carcinoma [2]. * **Non-comedo DCIS:** This includes patterns like cribriform, papillary, and solid. These are generally lower grade and are almost exclusively detected as incidental findings on screening mammography rather than physical examination [2]. **3. NEET-PG High-Yield Pearls:** * **Histology:** Paget cells are large, pale cells with abundant cytoplasm and prominent nucleoli, located within the squamous epithelium [1]. They are **PAS positive** (mucin-producing). * **Marker:** Paget cells almost always express **HER2/neu** over-expression [1]. * **Clinical Tip:** Any "eczema" of the nipple that does not respond to topical steroids must be biopsied to rule out Paget’s disease. * **Prognosis:** The prognosis of Paget’s disease depends on the stage of the underlying breast cancer, not the skin involvement itself [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1061-1062. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 452-453.

Question 320: What is true about proto-oncogenes?

A. They are normally involved in cell cycle proliferation. (Correct Answer)
B. They produce tumors.
C. They are normally involved in the suppression of tumor production.
D. Mutation of proto-oncogenes causes cancer.

Explanation: ### Explanation **1. Why Option A is Correct:** Proto-oncogenes are **normal cellular genes** [1] that encode proteins essential for regulating cell growth, differentiation, and survival [1]. Under physiological conditions, they act as the "accelerators" of the cell cycle, ensuring controlled proliferation [3]. Examples include growth factors (PDGF), growth factor receptors (ERBB2/HER2), signal transducers (RAS), and nuclear transcription factors (MYC) [2]. **2. Analysis of Incorrect Options:** * **Option B:** Proto-oncogenes do *not* produce tumors in their normal state. It is only when they undergo **gain-of-function mutations** or over-expression that they become **oncogenes**, which then drive tumorigenesis [2]. * **Option C:** This describes **Tumor Suppressor Genes** (e.g., *RB*, *TP53*). Tumor suppressors act as "brakes" to inhibit cell proliferation, whereas proto-oncogenes promote it [3]. * **Option D:** While a mutation in a proto-oncogene is a step toward malignancy, it does not *automatically* cause cancer. Carcinogenesis is a multi-step process requiring the accumulation of multiple mutations (including the inactivation of tumor suppressor genes and evasion of apoptosis). Furthermore, proto-oncogene mutations are typically **dominant**, meaning a mutation in just one allele is sufficient for transformation [2]. **3. NEET-PG High-Yield Pearls:** * **RAS:** The most common mutated proto-oncogene in human tumors (Point mutation) [2]. * **c-MYC:** Associated with Burkitt Lymphoma (t[8;14] translocation) [2]. * **ERBB2 (HER2/neu):** Amplified in approximately 20% of breast cancers; targeted by Trastuzumab [2]. * **Mechanism of Activation:** Proto-oncogenes convert to oncogenes via point mutations, chromosomal translocations, or gene amplification [2]. * **Knudson’s Two-Hit Hypothesis:** Applies to Tumor Suppressor Genes, not proto-oncogenes. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 228-229. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 291-293. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 291-292.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?